Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Atezolizumab |
Indication/Tumor Type | bladder urothelial carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | bladder urothelial carcinoma | sensitive | Atezolizumab | Phase II | Actionable | In a Phase II trial (IMvigor210), treatment with Tecentriq (atezolizumab) resulted in an objective response rate (ORR) of 23% (27/119) in cisplatin-ineligible patients with previously untreated, locally advanced or metastatic urothelial cancer, and ORR was 28% (9/32, 4 complete responses, 5 partial responses) in patients with immune cell CD274 (PD-L1) expression greater than or equal to 5% (PMID: 27939400; NCT02108652). | 27939400 |
CD274 positive | bladder urothelial carcinoma | sensitive | Atezolizumab | Guideline | Actionable | Tecentriq (atezolizumab) is included in guidelines as a first-line therapy (category 2B) for cisplatin-ineligible bladder urothelial carcinoma patients with immune cell CD274 (PD-L1) expression greater than or equal to 5% (NCCN.org). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
NCCN.org | Full reference... | |
(27939400) | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. | Full reference... |